Is Fortrea (FTRE) overvalued or fairly valued?

MarketChacha shows Fortrea's valuation in context — a forward P/E of about 17.2, a price-to-book of about 3.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Fortrea's revenue?

Fortrea reported revenue of $2.7B for FY2025, with net profit of $-986.2M, per official filings.

What is the share price of Fortrea (FTRE)?

Fortrea last traded at $18.46 (+3.1% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Fortrea

FTRE · NYSE · Healthcare · United States

$18.46+3.1%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:31 PM

Snapshot

TickerFTRE

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees14,000

HeadquartersDurham, United States

Market cap$1.7B

P/B3.3

Volume564.16K

Websitewww.fortrea.com

Filings tracked5

About Fortrea

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Profile as reported by Yahoo Finance.

Who owns it

Insiders1.0%
Institutions99.0%
Public & other0.0%

441 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.16.02%
Goldman Sachs Group Inc8.56%
Corvex Management LP4.91%
Sessa Capital IM, L.P.4.86%
State Street Corporation4.34%
Vanguard Capital Management LLC4.27%
Vanguard Portfolio Management LLC3.91%
AQR Capital Management, LLC3.49%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Margin has compressed by about 35.3 points over the period — profitability is trending down.

Net margin trend-0.9% → -36.2%

Margin has compressed by about 35.3 points over the period — profitability is trending down.

Return on equity-175.0%

Latest ROE of -175.0% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $657.0M · EPS 0.21

Est. earnings growth +77.4%

Next fiscal year

Rev $2.7B · EPS 1.08

Est. earnings growth +33.5%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$5.2752-wk range$18.67

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.7B

Day change

+3.1%

Fwd P/E

17.2

P/B

3.3

Beta

2.01

Revenue (FY2025)

$2.7B

Net margin

-36.2%

ROE

-175.0%

Revenue CAGR (2y)

-2.1%

EPS (FY2025)

-10.81

Net profit (FY2025)

$-986.2M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about FTRE

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$2.7B	$-986.2M	-10.81	-36.2%	-175.0%
FY2024	$2.7B	$-328.5M	-3.67	-12.2%	-24.1%
FY2023	$2.8B	$-25.2M	-0.29	-0.9%	-1.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$636.5M	$-23.6M	-0.25	-3.7%
2025Q3	$701.3M	$-15.9M	-0.17	-2.3%
2025Q2	$710.3M	$-374.9M	-4.14	-52.8%
2025Q1	$651.3M	$-562.9M	-6.25	-86.4%
2024Q3	$674.9M	$-27.9M	-0.31	-4.1%
2024Q2	$662.4M	$-138.4M	-1.55	-20.9%
2024Q1	$662.1M	$-101.0M	-1.13	-15.3%
2023Q3	$713.8M	$-14.0M	-0.16	-2.0%
2023Q2	$725.1M	$30.8M	0.35	4.2%
2023Q1	$693.9M	$12.5M	0.14	1.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change
SEC7/14/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/26/2026material
8-K — Shareholder vote results
SEC6/12/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.